Current advances in giant cell arteritis.
Curr Opin Neurol
; 34(1): 133-141, 2021 02 01.
Article
in English
| MEDLINE | ID: covidwho-1379488
ABSTRACT
PURPOSE OF REVIEW The aim of this study was to present the latest advances in giant cell arteritis (GCA) care, and recent national and international rheumatology societies guidance which influences clinical practice. RECENT FINDINGS:
Cranial ultrasound reduces diagnostic delay and improves clinical outcomes. Immediate high dose glucocorticoids remain the standard treatment for GCA. Controlled trial evidence using Tocilizumab, an interleukin-6 receptor antagonist, shows good clinical efficacy with steroid-sparing effects.SUMMARY:
Improved patient outcomes require formalizing pathways to diagnosis and closer liaison with rheumatology for long-term management with second-line therapies.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Giant Cell Arteritis
/
Practice Patterns, Physicians'
Type of study:
Diagnostic study
/
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Curr Opin Neurol
Journal subject:
Neurology
Year:
2021
Document Type:
Article
Affiliation country:
WCO.0000000000000889
Similar
MEDLINE
...
LILACS
LIS